ARCHIVES

Regorafenib Trial Meets Primary Endpoint; Overall Survival Improved by 29 Percent

This article is from The Cancer Letter archive.

Vol. 35 No. 1 | January 27, 2012

Download PDF Visit The Full Archive

Related Articles

Surgery, Radiation Effective For Older Women, Study Finds

September 24, 2004

Groups Urge FDA To Take Action Against Tobacco Products

June 27, 2014

Tykerb And Trastuzumab Showed Increase In PFS For HER2+ Breast Cancer In Study

May 30, 2008

NCI Programs: HMO Research Network wins $16 Million Grant for Prevention Studies

July 30, 1999

Acting Commissioner Tells Grassley He Supports “Academic Freedom” at The Agency, but “At A Proper Time.”

December 1, 2006

Review Group Urges Increased Funding For NCI AIDS Drug Discovery Program

December 3, 1999